[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112022004712A2 - Compostos e métodos de imunoterapia - Google Patents

Compostos e métodos de imunoterapia

Info

Publication number
BR112022004712A2
BR112022004712A2 BR112022004712A BR112022004712A BR112022004712A2 BR 112022004712 A2 BR112022004712 A2 BR 112022004712A2 BR 112022004712 A BR112022004712 A BR 112022004712A BR 112022004712 A BR112022004712 A BR 112022004712A BR 112022004712 A2 BR112022004712 A2 BR 112022004712A2
Authority
BR
Brazil
Prior art keywords
domain
methods
cell
immunotherapy
her2
Prior art date
Application number
BR112022004712A
Other languages
English (en)
Inventor
A Vallera Daniel
S Miller Jeffrey
Martin Felices
Martin Schroeder
Original Assignee
Gt Biopharma Inc
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gt Biopharma Inc, Univ Minnesota filed Critical Gt Biopharma Inc
Publication of BR112022004712A2 publication Critical patent/BR112022004712A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

compostos e métodos de imunoterapia. a presente invenção refere-se a um composto de imunoterapia que inclui um domínio de envolvimento de células nk, um domínio de ativação nk e um domínio de direcionamento. o domínio de direcionamento se liga seletivamente ao her2, her3 ou ao complexo heterodímero her2/her3 e está ligado de maneira funcional ao domínio de ativação de nk e ao domínio de envolvimento das células nk. o composto pode ser administrado a um indivíduo para induzir a morte de uma célula cancerígena mediada por nk, para estimular a expansão das células nk no indivíduo e/ou para tratar o câncer.
BR112022004712A 2019-09-16 2020-09-15 Compostos e métodos de imunoterapia BR112022004712A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962901198P 2019-09-16 2019-09-16
PCT/US2020/050851 WO2021055342A1 (en) 2019-09-16 2020-09-15 Immunotherapy compounds and methods

Publications (1)

Publication Number Publication Date
BR112022004712A2 true BR112022004712A2 (pt) 2022-06-14

Family

ID=74883667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004712A BR112022004712A2 (pt) 2019-09-16 2020-09-15 Compostos e métodos de imunoterapia

Country Status (10)

Country Link
US (1) US20220324972A1 (pt)
EP (1) EP4031565A4 (pt)
JP (1) JP2022548145A (pt)
KR (1) KR20220087441A (pt)
CN (1) CN115023435A (pt)
AU (1) AU2020350524A1 (pt)
BR (1) BR112022004712A2 (pt)
CA (1) CA3154158A1 (pt)
IL (1) IL291343A (pt)
WO (1) WO2021055342A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024534467A (ja) * 2021-09-16 2024-09-20 ジーティー バイオファーマ インコーポレイテッド Ｐｄ－ｌ１標的指向融合タンパク質及びそれらの使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018572A2 (en) * 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
EP3066470A4 (en) * 2013-11-05 2017-05-31 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
KR102503476B1 (ko) * 2014-06-30 2023-02-24 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
SG11201802794PA (en) * 2015-10-06 2018-05-30 Univ Minnesota Therapeutic compounds and methods
AU2017238172B2 (en) * 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF

Also Published As

Publication number Publication date
KR20220087441A (ko) 2022-06-24
JP2022548145A (ja) 2022-11-16
US20220324972A1 (en) 2022-10-13
WO2021055342A1 (en) 2021-03-25
CN115023435A (zh) 2022-09-06
CA3154158A1 (en) 2021-03-25
IL291343A (en) 2022-05-01
EP4031565A1 (en) 2022-07-27
AU2020350524A1 (en) 2022-04-21
EP4031565A4 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
CL2022002448A1 (es) Constructos de anticuerpo para flt3 y cd3 (divisional sol.: 201800269)
BR112021011431A2 (pt) Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
BR112019002035A2 (pt) tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
MA40074A (fr) Composés liant ras multivalents
BR112016026559A8 (pt) uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
BR112017010094A2 (pt) anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
BR112014027291A2 (pt) composições de anticorpos pan-her humanizados
CR20150054A (es) Anticuerpos anti-cxcr5 humanizados derivados de los mismos y su uso
PE20160753A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
BR112018013653A2 (pt) anticorpos anti-pd-1
CL2019000585A1 (es) Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos.
BR112012016820A2 (pt) Metodos para tratamento de cancer de seio
BR112015027309A2 (pt) anticorpo, composição, método de tratamento e uso de um anticorpo
AR115288A1 (es) Anticuerpos humanizados contra el psma
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
MX2024004299A (es) Anticuerpos anti-pmel17 y conjugados de los mismos.
BR112023004830A2 (pt) Métodos para tratamento de mieloma múltiplo